MediciNova Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

MediciNova şirketinin toplam hissedar öz sermayesi $55.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $58.1M ve $3.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$42.28m
Eşitlik	US$55.07m
Toplam yükümlülükler	US$3.05m
Toplam varlıklar	US$58.12m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4875 'nin kısa vadeli varlıkları ( $43.3M ) kısa vadeli yükümlülüklerini ( $2.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4875 şirketinin kısa vadeli varlıkları ( $43.3M ) uzun vadeli yükümlülüklerini ( $456.9K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4875 borçsuzdur.

Borcun Azaltılması: 4875 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4875 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 4875, serbest nakit akışı her yıl % 2.6 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

MediciNova Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova, Inc., Annual General Meeting, Jun 11, 2024

MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe

Less than half of directors are independent

MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers

MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

Independent Director recently sold JP¥95k worth of stock

MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada

First half 2022 earnings released

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022

MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

MediciNova, Inc. Announces Executive Changes

MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Price target decreased to JP¥1,100

MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022

MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research

MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada

MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS

MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND

Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology

MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

Chief Financial Officer Edward Stepanow has left the company

MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index

MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Forecast breakeven pushed back to 2024

MediciNova, Inc. a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

Independent Director recently sold JP¥1.9m worth of stock

New 90-day high: JP¥798

MediciNova, Inc. Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-Induced Lung Injury

MediciNova, Inc. Announces Update on SARS-CoV-2 Vaccine for Covid-19

New 90-day high: JP¥670

MediciNova, Inc. announced that it has received $19.999999 million in funding from 3D Investment Partners Pte. Ltd

MediciNova, Inc. Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (Ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Japan

MediciNova, Inc. announced that it expects to receive $19.999999 million in funding from 3D Investment Partners Pte. Ltd

Medicinova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS

New 90-day low: JP¥456

MediciNova, Inc. Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 in Progressive MS Published in Multiple Sclerosis Journal

New 90-day high: JP¥635

MediciNova, Inc. Announces Positive Findings on MN-001 in Acute Liver Injury Model

New 90-day low: JP¥538

MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology

MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies against SARS-CoV-2 in Mice using BC-PIV Vector Technology